Effexor and Posterior capsule opacification - a phase IV clinical study of FDA data

Summary:

Posterior capsule opacification is reported as a side effect among people who take Effexor (venlafaxine hydrochloride), especially for people who are female, 60+ old, also take Aredia, and have Bone loss.

The phase IV clinical study analyzes which people have Posterior capsule opacification when taking Effexor. It is created by eHealthMe based on reports of 92,291 people who have side effects when taking Effexor from the FDA, and is updated regularly.

What is Effexor?

Effexor has active ingredients of venlafaxine hydrochloride. It is often used in depression. eHealthMe is studying from 99,493 Effexor users. Check the latest studies of Effexor.

What is Posterior capsule opacification?

Posterior capsule opacification is found to be associated with 139 drugs and 143 conditions by eHealthMe. Check the latest studies of Posterior capsule opacification.

On Jul, 04, 2026

92,291 people reported to have side effects when taking Effexor.
Among them, 27 people (0.03%) have Posterior capsule opacification.

Could Effexor cause Posterior capsule opacification?

Among these 27 people:

What is the gender of people who have Posterior capsule opacification when taking Effexor? *

female: 59.26 %
male: 40.74 %

What is the age of people who have Posterior capsule opacification when taking Effexor? *

What are other drugs people take besides Effexor? *

What are other side effects people have besides Posterior capsule opacification? *

Pain: 27 people, 100.00%
Osteonecrosis Of Jaw (death of bone of jaw): 26 people, 96.30%
Fall: 26 people, 96.30%
General Physical Health Deterioration (weak health status): 25 people, 92.59%
Osteomyelitis (infection of bone): 24 people, 88.89%
Haematoma (collection of blood outside the blood vessels): 17 people, 62.96%
Multiple Myeloma (cancer of the plasma cells): 16 people, 59.26%
Spinal Osteoarthritis (joint cartilage loss in spine): 16 people, 59.26%
Visual Acuity Reduced (reduced clearness of vision): 16 people, 59.26%
Infection: 15 people, 55.56%

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 11 people, 40.74%
Bone Loss: 11 people, 40.74%
Sleep Disorder: 1 person, 3.70%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 1 person, 3.70%
Post-Traumatic Stress Disorder: 1 person, 3.70%
Panic Disorder: 1 person, 3.70%
Grand Mal Convulsion (a type of generalized seizure that affects the entire brain): 1 person, 3.70%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 3.70%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 3.70%
Aplastic Anemia: 1 person, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Effexor and have Posterior capsule opacification?

- Check whether Posterior capsule opacification is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Effexor:

Effexor (99,493 reports)

Browse all side effects of Effexor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Posterior capsule opacification:

Posterior capsule opacification (139 drugs)

Browse all the conditions that are associated with Posterior capsule opacification:

Posterior capsule opacification (143 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on venlafaxine hydrochloride (the active ingredients of Effexor) and Effexor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.